
    
      300 MDS patients will be recruited for trial. They will be randomly administrated with ATO +
      decitabine (n=200) or decitabine alone (n=100). The RSF, CR ratio, overall survival will be
      compared between the two arms. Importantly, TP53 status will be sequenced and its correlation
      with RSF, CR ratio, overall survival within the two arms will be investigated.
    
  